drugset / Trial / NCT06492525

A Study To Evaluate The Effect Of Rifampicin Or Ltraconazole On Pharmacokinetics Of Ensartinib In Healthy Volunteers

NCT06492525

Phase 1 Not yet recruiting 36 enrolled Betta Pharmaceuticals Co., Ltd.
Non-randomizedCrossoverOpen-labelOther

Summary

The purpose of this study is to estimate the effect of rifampicin or itraconazole on the single dose PK of ensartinib.

Timeline

Start
2024-07
Primary completion
2024-10
Completion
2024-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ensartinib Small molecule 100 mg Oral
Subject Ensartinib Small molecule 225 mg Oral
Subject Itraconazole Small molecule 200 mg
Subject Rifampin Small molecule 600 mg

Indications

No indication recorded.